The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2022 | The importance of MRD in AML prognosis and therapy
Arnon Nagler, Chaim Sheba Medical Center, Tel-Aviv, Israel, explains comments on the importance of measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML). The prognosis of patients with AML is currently based on MRD detection. Patients that are MRD negative pre-transplant have a much lower relapse rate, which translates to better survival rates. Detection of MRD post-transplant is an indicator of relapse allowing for early intervention and treatment. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
